Biogen (NSDQ:BIIB) said yesterday that it inked an $890 million deal to sell a Denmark-based manufacturing site to Fujifilm (TSE:4901). The site, located in Hillerød, includes a biologics production facility with assembly, labeling and packing capabilities as well as quality control laboratories and warehouses, Cambridge, Mass.-based Biogen said. The facility also has approximately 800 employees who are […]
Search Results for: Biogen Idec
Biogen to sell Denmark-based manufacturing site to FujiFilm for $890m
Report: Biogen CEO eyes medical device market
After taking the helm at Biogen (NSDQ:BIIB) in 2016, Michel Vounatsos made use of acquisitions and geographic expansion to grow the company. Now, Vounatsos is reportedly considering another possible opportunity to differentiate the pharmaceutical player. The company’s chief executive hinted in an interview with Globes that Biogen could make a move into the medical technology space. Get the full […]
Biogen lifts outlook after strong Q2
Shares in Biogen (NSDQ:BIIB) rose today after the biopharmaceutical company met expectations on Wall Street with its second quarter results. The Cambridge, Mass.-based company posted profits of $863 million, or $4.07 per share, on sales of $3.1 billion for the 3 months ended June 30, for bottom-line loss of -18% on sales growth of 6% compared with […]
Federal investigators subpoena Biogen over MS drug prices
Biogen (NSDQ:BIIB) said on Thursday that it received a subpoena in December last year from federal investigators about the prices of its top-selling multiple sclerosis drugs, Tecfidera, Avonex, Tysabri and Plegridy. In its annual regulatory filing, the company wrote that the investigators inquired about “government price reporting, rebate payments and Biogen’s co-pay assistance programs.” While Cambridge, Mass.-based Biogen […]
Biogen beats Q4 earnings, misses on full-year rev forecast
Shares in Biogen (NSDQ:BIIB) rose this week after the biopharmaceutical company met expectations on Wall Street with its 4th quarter financial results, but pegged its full-year revenue forecast lower than analysts expected. The Cambridge, Mass.-based company posted profits of $649.2 million, or $2.99 per share, on sales of $2.87 billion for the 3 months ended Dec. […]
Biogen, Ionis win FDA approval for first spinal muscular atrophy drug
Biogen (NSDQ:BIIB) said last week that it won FDA approval for its spinal muscular atrophy treatment, Spinraza. The drug is the 1st treatment approved in the U.S. for spinal muscular atrophy, a progressive and often fatal genetic disease that causes muscle weakness in infants and toddlers. The FDA previously granted Biogen’s application fast track designation […]
Biogen gets European approval on injectable pen for MS therapy

Biogen Idec (NSDQ:BIIB) announced European approval on an injectable pen that delivers its top-selling multiple sclerosis drug Avonex.
Avonex is used as a treatment for relapsing forms of MS. The drug slows the progression of physical disability and reduces relapses.
Weston, Mass.-based Biogen makes Avonex at a manufacturing facility in North Carolina’s Research Triangle Park.
Zimmer Biomet elevates Delp to Americas prez | Personnel Moves | January 22, 2017
Zimmer Biomet (NYSE:ZBH) said this week it tapped Robert Delp as its new Americas president, lifting him from his previous position as VP of US sales. Delp will replace former Americas prez Stuart Kleopfer, who is retiring from the position but will continue to work with the company while Delp transitions into his position. The shift […]
Schellhorn out, Emerson in as Monteris CEO | Personnel Moves July 25, 2016
Schellhorn out, Emerson in as Monteris CEO Monteris Medical said last week it tapped ex-Galil Medical prez & CEO Martin Emerson as its new president and chief executive officer, replacing John Schellhorn who left earlier this year. Emerson spent 8 years as prez & CEO of Galil Medical, which was acquired in June this year […]
Johnson & Johnson, Medtronic make BCG’s most innovative list
Johnson & Johnson (NYSE:JNJ) and Medtronic (NYSE:MDT) were named in the Boston Consulting Group’s list of the 50 most innovative companies this year at the 20 and 42 spot, respectively. Apple (NSDQ:AAPL) and Google (NSDQ:GOOG) took the top 2 spots on the list. Other notable entries were Gilead at number 8, Bayer‘s (ETR:BAYN) at 11, Biogen (NSDQ:BIIB) at […]